Navigation Links
Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments

Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

The phase II clinical research study uses vascular endothelial growth factor-2 (VEGF-2) in the form of a solution containing a DNA plasmid that is delivered using catheterization to heart tissue that has been damaged from insufficient blood flow.

Once the catheter reaches the targeted site inside of the heart, the VEGF-2 is injected into the heart muscle region with inadequate blood supply. The DNA plasmid is then taken up by the middle muscular layer of the heart wall near the injection site. Inside the cell, the DNA encoded VEGF-2 expresses itself which in turn stimulates the growth of new blood vessels by promoting the proliferation of endothelial cells in the heart.

New blood vessels are required to provide oxygen-carrying blood to heart muscles to compensate for the blocked heart arteries. The subsequent, improved blood flow relieves the painful symptoms of angina.

"The process of growing new blood vessels, or angiogenesis, should occur over the course of four to eight weeks following the procedure which is done in the cardiac catheterization lab at Rush," said Dr. Gary L. Schaer, the principal investigator of the trial at Rush and director of the Rush Cardiac Catheterization Labs. "The patient goes home the next day." Several patients have received the gene therapy and all are doing well.

Individuals who may be candidates for this gene therapy study trial must have moderate to severe angina, but cannot also be candidates for treatment using angioplasty or bypass surgery. Angioplasty involves a catheterization with a balloon-like device that opens blocked arteries, while bypass surgery requires open-heart surgery to place veins removed from the patient's leg or arteries taken from
'"/>

Source:Rush University Medical Center


Page: 1 2

Related biology news :

1. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
2. Researchers Closer To Helping Hearing-Impaired Using Stem Cells
3. Using nanoparticles, in vivo gene therapy activates brain stem cells
4. Using computers and DNA to count bacteria
5. Using the genomic shortcut to predict bacterial behavior
6. Using natures most primitive anti-viral defense system to find new approaches to cancer research
7. Using dental X-rays to detect osteoporosis
8. Using brain scans, researchers find evidence for a two-stage model of human perceptual learning
9. Using nanomagnets to enhance medical imaging
10. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
11. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
Post Your Comments:
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... This news release is available in German . ... power are inherently intermittent energy sources. If a large amount ... in the future, excess energy will have to be stored ... for. However, existing storage capacities are far from adequate for ... better technologies. One important focus lies on battery systems that ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A) today announced that its breakthrough Human Genome CGH ... Peter MacCallum Cancer Centre in a three-year study designed ... lining of the chest, the abdominal cavity and around ... Due to its active mining and manufacturing of asbestos ...
... The human fossil evidence from the Mladec Caves in Moravia, ... proven for the first time, through modern radiocarbon dating, to ... modern humans in Europe. , A team of researchers from ... Vienna in Austria and from the Washington University in St. ...
... Studying phage, a primitive class of virus that infects ... researchers have gained insight into the driving force behind ... in the past to occur through the release of ... all phages (also known as bacteriophages) are formed of ...
Cached Biology News:Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma 2Oldest cranial, dental and postcranial fossils of early modern European humans confirmed 2Basis for DNA ejection from single phage particles 2
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... ... most complex toxicology study designs in South Korea , ... Cedar Knolls, NJ and Daejeon, South Korea (PRWEB) ... solutions and the developer of Pristima™ the premier preclinical solution on the market, is ...
... , , ABBOTT PARK, Ill., Aug. ... expansion of the company,s XIENCE V(R) USA post-approval study designed to ... Everolimus Eluting Coronary Stent System in a real-world clinical setting out ... from the XIENCE V USA trial to be eligible to cross ...
... , , , ... MON ) R&D pipeline is on the verge of a technology ... for growers and has the company poised to meet its goals ... and president, will tell investors today. , , ...
Cached Biology Technology:Korea Institute of Toxicology Implementing Xybion's Pristima™ 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 3Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7
...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant canine ... culture supernates and serum.1 Each kit contains ... fifteen 96-well plates, provided that the following ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Biology Products: